The short interest in VIVUS (NASDAQ:VVUS) has increased from 13,678,851 on May 31,2016 to 13,869,563 on June 15,2016. The change was measured at 190,712 shares or 1.4%. The leftover shorts were 14.2% of the floated shares. The days to cover are 27, given the average daily volume of 505,157 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
VIVUS (NASDAQ:VVUS): The stock was completely flat for the day, closing at $1.10 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $1.05, the stock touched an intraday high of $1.12 and a low of $1.02. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $1.10. The total trading volume on Friday was 11,011,551.
The company shares have dropped -52.79% from its 1 Year high price. On Jun 29, 2015, the shares registered one year high at $2.47 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $1.20 and the 200 Day Moving Average price is recorded at $1.21.
VIVUS (NASDAQ:VVUS) has tumbled 5.17% during the past week and has dropped 10.57% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 3.6%. VIVUS (NASDAQ:VVUS) has underperformed the index by 7.86% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42,000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. As of September 18, 2014, the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.